NRx Pharmaceuticals (NASDAQ:NRXP) Shares Up 0.7% – Time to Buy?

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) rose 0.7% on Friday . The company traded as high as $4.39 and last traded at $4.27. 424,182 shares were traded during mid-day trading, a decline of 50% from the average daily volume of 856,493 shares. The stock had previously closed at $4.24.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. BTIG Research restated a “buy” rating and set a $25.00 price target on shares of NRx Pharmaceuticals in a research note on Tuesday, March 24th. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, June 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Friday, May 8th. D. Boral Capital reissued a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a report on Tuesday, May 5th. Finally, Ascendiant Capital Markets raised their target price on NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $38.25.

NRx Pharmaceuticals Stock Performance

The company’s 50 day moving average price is $3.85 and its 200 day moving average price is $2.79. The company has a market cap of $154.70 million, a price-to-earnings ratio of -3.92 and a beta of 2.19.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its earnings results on Friday, May 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $1.07 million for the quarter, compared to analyst estimates of $19.43 million. As a group, analysts predict that NRx Pharmaceuticals, Inc. will post -0.3 EPS for the current year.

Institutional Trading of NRx Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Anson Funds Management LP increased its holdings in shares of NRx Pharmaceuticals by 50.3% during the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock worth $8,249,000 after buying an additional 1,018,853 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after acquiring an additional 82,781 shares in the last quarter. AdvisorShares Investments LLC grew its position in NRx Pharmaceuticals by 28.2% during the 1st quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock worth $896,000 after acquiring an additional 92,463 shares during the last quarter. Commonwealth Equity Services LLC bought a new stake in NRx Pharmaceuticals during the 4th quarter worth approximately $994,000. Finally, Geode Capital Management LLC increased its holdings in NRx Pharmaceuticals by 17.8% during the 4th quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock valued at $593,000 after purchasing an additional 33,004 shares in the last quarter. 4.27% of the stock is owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.